We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of MyoKardia, Inc. (“MyoKardia” or the “Company”) (NASDAQ: MYOK) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the deal, Bristol Myers Squibb will acquire MyoKardia for $225.00 per share in cash.
The MyoKardia merger investigation concerns whether the Board of MyoKardia has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
To receive more information, please fill out the form.